These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23813109)

  • 1. High-dose (2.0 mg) intravitreal ranibizumab for recalcitrant radiation retinopathy.
    Finger PT; Chin KJ
    Eur J Ophthalmol; 2013; 23(6):850-6. PubMed ID: 23813109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Trial of Monthly Versus As-Needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1-Year Outcomes.
    Schefler AC; Fuller D; Anand R; Fuller T; Moore C; Munoz J; Kim RS;
    Am J Ophthalmol; 2020 Aug; 216():165-173. PubMed ID: 32278771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study.
    Finger PT; Chin KJ; Semenova EA
    Eur J Ophthalmol; 2016; 26(1):60-6. PubMed ID: 26391167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal anti-VEGF bevacizumab (Avastin) for external beam related radiation retinopathy.
    Finger PT; Mukkamala SK
    Eur J Ophthalmol; 2011; 21(4):446-51. PubMed ID: 21218391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma.
    Mason JO; Albert MA; Persaud TO; Vail RS
    Retina; 2007 Sep; 27(7):903-7. PubMed ID: 17891015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy.
    Bakri SJ; Larson TA
    Semin Ophthalmol; 2015 Jul; 30(4):276-80. PubMed ID: 24251435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monthly intravitreal bevacizumab for macular edema after iodine-125 plaque radiotherapy of uveal melanoma.
    Mashayekhi A; Rojanaporn D; Al-Dahmash S; Shields CL; Shields JA
    Eur J Ophthalmol; 2014; 24(2):228-34. PubMed ID: 23934823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
    Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
    Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
    Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
    Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials.
    Boyer DS; Nguyen QD; Brown DM; Basu K; Ehrlich JS;
    Ophthalmology; 2015 Dec; 122(12):2504-13.e1. PubMed ID: 26452713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
    Tan MH; McAllister IL; Gillies ME; Verma N; Banerjee G; Smithies LA; Wong WL; Wong TY
    Am J Ophthalmol; 2014 Jan; 157(1):237-247.e1. PubMed ID: 24112635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE.
    Pieramici DJ; Wang PW; Ding B; Gune S
    Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for radiation-induced cystoid macular oedema in patients with nasopharyngeal carcinoma: a clinical series.
    Subrayan V; Khaw KW; Peyman M; Koay AC; Tajunisah I
    Ophthalmologica; 2013; 229(4):208-11. PubMed ID: 23548379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
    Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
    Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
    Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
    Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
    Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
    Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
    Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.